Insider · CIK 0001866289
Alissa Neufeld
Files at SNFCA (SECURITY NATIONAL FINANCIAL CORP), LFVN (Lifevantage Corp). First filing -, latest -.
In brief
Alissa Neufeld files SEC Form 4 as officer at SNFCA (SECURITY NATIONAL FINANCIAL CORP), and also at LFVN (Lifevantage Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Alissa Neufeld has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | SNFCA SECURITY NATIONAL FINANCIAL CORP | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $8.79 | $879k | 100,000 | 29 d ago |
| Jul 1, 2026 | LFVN Lifevantage Corp | FTax withholding Common Stock | -1,342 | $6.25 | $8,388 | 112,744 | Jul 6, 2026 |
| Apr 1, 2026 | LFVN Lifevantage Corp | FTax withholding Common Stock | -1,446 | $4.20 | $6,073 | 114,086 | Apr 3, 2026 |
| Jan 1, 2026 | LFVN Lifevantage Corp | FTax withholding Common Stock | -1,445 | $6.16 | $8,901 | 115,532 | Jan 5, 2026 |
| Oct 1, 2025 | LFVN Lifevantage Corp | FTax withholding Common Stock | -1,283 | $9.56 | $12k | 116,977 | Oct 3, 2025 |
| Aug 31, 2025 | LFVN Lifevantage Corp | MOption exercise Common Stock | +14,498 | $0.00 | $0 | 115,103 | Sep 3, 2025 |
| Aug 31, 2025 | LFVN Lifevantage Corp | MOption exercise Common Stock | +18,886 | $0.00 | $0 | 133,989 | Sep 3, 2025 |
| Aug 31, 2025 | LFVN Lifevantage Corp | FTax withholding Common Stock | -15,729 | $13.10 | $206k | 118,260 | Sep 3, 2025 |
| Aug 31, 2025 | LFVN Lifevantage Corp | MOption exercise Performance Restricted Stock Unitsderivative | -14,498 | $0.00 | $0 | 4,832 | Sep 3, 2025 |
| Aug 31, 2025 | LFVN Lifevantage Corp | MOption exercise Performance Restricted Stock Unitsderivative | -18,886 | $0.00 | $0 | 9,443 | Sep 3, 2025 |
| Aug 26, 2025 | LFVN Lifevantage Corp | AGrant or award Common Stock | +9,036 | $0.00 | $0 | 100,605 | Aug 28, 2025 |
| Aug 26, 2025 | LFVN Lifevantage Corp | AGrant or award Performance Restricted Stock Unitsderivative | +13,554 | $0.00 | $0 | 13,554 | Aug 28, 2025 |
| Jul 1, 2025 | LFVN Lifevantage Corp | MOption exercise Common Stock | +2,667 | $0.00 | $0 | 94,368 | Jul 3, 2025 |
| Jul 1, 2025 | LFVN Lifevantage Corp | FTax withholding Common Stock | -2,799 | $13.39 | $37k | 91,569 | Jul 3, 2025 |
| Jul 1, 2025 | LFVN Lifevantage Corp | MOption exercise Performance Restricted Stock Unitsderivative | -2,667 | $0.00 | $0 | 0 | Jul 3, 2025 |
| Apr 1, 2025 | LFVN Lifevantage Corp | MOption exercise Common Stock | +2,667 | $0.00 | $0 | 94,500 | Apr 3, 2025 |
| Apr 1, 2025 | LFVN Lifevantage Corp | FTax withholding Common Stock | -2,799 | $15.79 | $44k | 91,701 | Apr 3, 2025 |
| Apr 1, 2025 | LFVN Lifevantage Corp | MOption exercise Performance Restricted Stock Unitsderivative | -2,667 | $0.00 | $0 | 2,667 | Apr 3, 2025 |
Questions about Alissa Neufeld
Answered from the filings on this page, as of the latest one.
Is Alissa Neufeld buying or selling?
Alissa Neufeld has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Alissa Neufeld's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alissa Neufeld has 0.
Where does Alissa Neufeld file Form 4?
Alissa Neufeld has filed Form 4 at SNFCA (SECURITY NATIONAL FINANCIAL CORP) as Chief Legal Officer & Corp Sec; LFVN (Lifevantage Corp) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.